Mental Health
mental health conditions affect millions
Mental Health Conditions
causes and treatment strategies may be wide-ranging
May 1, 2026
Mental health conditions affect millions, significantly impacting plan sponsors and their members. Mental health journeys are unique but there are keys to helping those with mental health conditions find their individualized path to healing.
PBIRx Intelligence
Learn how PBIRx helps our clients save while ensuring appropriate access and adherence to mental health treatments - below
What is mental health?
What is Infertility?
Mental health encompasses many facets and conditions
What is mental health and what are some common disorders?
Prevalence of Mental Health Conditions
~23% of the US adult population
National Institute of Health (NIH) estimates that 23% of the US adult population live with a mental illness
Treatment of Mental Health Conditions
Combining non-pharmacological approaches with medications when appropriate
How are mental health disorders treated?
Key New Drugs on the Market for Mental Health
- Drug Name
- Exxua
- Zurzuvae
- Auvelity
- Igalmi
- Approval Date
- Sep 2023
- August 2023
- August 2022
- April 2022
- Indication
- Major Depressive Disorder
- Postpartum Depression
- Major Depressive Disorder
- Agitation associated with schizophrenia or bipolar disorder
- Approximate Monthly Cost
- $1,500
- $15,750
- $565
- $1,008
- Dosage Form
- Oral Tablet
- Oral Capsule
- Oral Tablet
- Sublingual Film
Key mental health treatment observations
-
- Exxua has some key advantages as compared to its predecessor, buspirone. It has a longer half life and better affinity for the active receptor site which allows for once daily dosing, rather than multiple doses per day.
- Zurzuvae is the first and only drug approved to treat postpartum depression, which impacts approximately 10-15% of women.
- Auvelity acts on the NMDA receptor, which is unlike any other oral antidepressant.
- IGALMI is the only sublingual film FDA approved for reducing agitation related to bipolar disorder.
- Lybalvi should not be taken within 7 days of short acting opioids and 14 days of long-acting opioids as one of its ingredients can cause opioid withdrawals.
PBIRx Intelligence
PBIRx helps our clients ensure appropriate access and utilization
PBIRx PharmD Mental Health Specialists help our clients ensure appropriate access to, and utilization of, mental health treatments
PBIRx will continue to be at the forefront in providing informed guidance to our valued client partners as they navigate the evolving landscape. Our team of PharmDs and pharmacy experts work at the granular level to identify cost-saving opportunities without compromising patient care. With our support, patients can access the medications they need to manage their mental health conditions, while payers can achieve cost savings. Contact us today to learn more about how we can help you manage your medication costs.PBIRx Intelligence Partnering with you to manage your pharmacy benefit spend
Author:
Nabil Khan, PharmD, RPh
Mental Health Organization and Resources




2025 PBIRx